NCT04773587: A reported trial by Arcutis Biotherapeutics, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04773587 |
|---|---|
| Title | A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 27, 2021 |
| Completion date | Aug. 30, 2022 |
| Required reporting date | Aug. 30, 2025, midnight |
| Actual reporting date | Aug. 2, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |